EMFLAZA
Total Payments
$1.3M
Transactions
1,396
Doctors
560
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $3,722 | 133 | 67 |
| 2023 | $15,718 | 227 | 146 |
| 2022 | $116,396 | 255 | 186 |
| 2021 | $24,671 | 231 | 162 |
| 2020 | $26,231 | 81 | 64 |
| 2019 | $1.1M | 469 | 169 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $882,465 | 8 | 68.1% |
| Royalty or License | $175,000 | 1 | 13.5% |
| Consulting Fee | $168,200 | 74 | 13.0% |
| Food and Beverage | $36,531 | 1,126 | 2.8% |
| Education | $15,501 | 151 | 1.2% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $6,969 | 4 | 0.5% |
| Travel and Lodging | $5,671 | 30 | 0.4% |
| Space rental or facility fees (teaching hospital only) | $4,750 | 2 | 0.4% |
Payments by Type
Research
$882,465
8 transactions
General
$412,622
1,388 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY COMPARING THE BIOEQUIVALENCE OF DEFLAZACORT DISPERSIBLE TABLET TO EMFLAZA DEFLAZACORT TABLET IN HEALTHY ADULT SUBJECTS | PTC Therapeutics, Inc. | $866,915 | 0 |
| A PHASE 1 STUDY TO INVESTIGATE THE ABSORPTION AND METABOLISM OF 14C-DEFLAZACORT FOLLOWING SINGLE ORAL DOSE ADMINISTRATION IN HEALTHY SUBJECTS | PTC Therapeutics, Inc. | $15,550 | 0 |
Top Doctors Receiving Payments for EMFLAZA
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Rochester, NY | $1.1M | 16 |
| , MD | Student in an Organized Health Care Education/Training Program | Dallas, TX | $20,724 | 12 |
| , M.D | Pediatrics | Philadelphia, PA | $14,575 | 2 |
| , M.D | Pediatric Critical Care Medicine | Columbus, OH | $12,113 | 4 |
| , MD | Neurology with Special Qualifications in Child Neurology | Little Rock, AR | $10,086 | 4 |
| , M.D | Physical Medicine & Rehabilitation | San Juan, PR | $9,661 | 43 |
| , MD | Sleep Medicine | San Antonio, TX | $9,501 | 13 |
| , MD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $8,828 | 4 |
| , M.D | Neurology with Special Qualifications in Child Neurology | Miami, FL | $8,374 | 8 |
| , M.D | Pediatric Rehabilitation Medicine | Sacramento, CA | $7,622 | 3 |
| , MD | Neurology with Special Qualifications in Child Neurology | Houston, TX | $6,878 | 5 |
| , M.D | Clinical Genetics (M.D.) | Galveston, TX | $6,659 | 9 |
| , MD | Pediatric Endocrinology | Philadelphia, PA | $5,800 | 3 |
| , MD | Student in an Organized Health Care Education/Training Program | Dallas, TX | $5,681 | 5 |
| , MD | Neurology | Philadelphia, PA | $5,400 | 1 |
| , MD | Neuromuscular Medicine | Nashville, TN | $4,995 | 1 |
| , MD | Neurology with Special Qualifications in Child Neurology | Chicago, IL | $4,925 | 4 |
| , MD | Pediatric Gastroenterology | Columbus, OH | $4,853 | 2 |
| , M.D | Pediatric Rehabilitation Medicine | Seattle, WA | $3,600 | 1 |
| , MD | Vascular Neurology | Rochester, NY | $3,200 | 1 |
| , MD | Child & Adolescent Psychiatry | Minneapolis, MN | $3,189 | 11 |
| , M.D | Physical Medicine & Rehabilitation | Akron, OH | $3,135 | 13 |
| , MD/PHD | Neurology with Special Qualifications in Child Neurology | Philadelphia, PA | $2,808 | 9 |
| , NP | Pediatrics | New York, NY | $1,869 | 7 |
| , M.D | Pediatrics | Detroit, MI | $1,782 | 16 |
Ad
Manufacturing Companies
- PTC Therapeutics, Inc. $1.3M
Product Information
- Type Drug
- Total Payments $1.3M
- Total Doctors 560
- Transactions 1,396
About EMFLAZA
EMFLAZA is a drug associated with $1.3M in payments to 560 healthcare providers, recorded across 1,396 transactions in the CMS Open Payments database. The primary manufacturer is PTC Therapeutics, Inc..
Payment data is available from 2019 to 2024. In 2024, $3,722 was paid across 133 transactions to 67 doctors.
The most common payment nature for EMFLAZA is "Unspecified" ($882,465, 68.1% of total).
EMFLAZA is associated with 2 research studies, including "AN OPEN-LABEL, RANDOMIZED, SINGLE-DOSE, TWO-PERIOD CROSSOVER STUDY COMPARING THE BIOEQUIVALENCE OF DEFLAZACORT DISPERSIBLE TABLET TO EMFLAZA DEFLAZACORT TABLET IN HEALTHY ADULT SUBJECTS" ($866,915).